Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L3RO
|
||||
| Former ID |
DIB012699
|
||||
| Drug Name |
TAS-119
|
||||
| Indication | Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10:C00-C75, C7A, C7B, D10-D36, D3A] | Phase 1 | [1] | ||
| Company |
Taiho oncology
|
||||
| Target and Pathway | |||||
| Target(s) | Aurora kinase A | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Pathway Interaction Database | Aurora B signaling | ||||
| Signaling by Aurora kinases | |||||
| Integrin-linked kinase signaling | |||||
| PLK1 signaling events | |||||
| Aurora A signaling | |||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
| Regulation of PLK1 Activity at G2/M Transition | |||||
| WikiPathways | EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | |||||
| Gastric Cancer Network 1 | |||||
| Integrated Breast Cancer Pathway | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040598) | ||||
| REF 2 | TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A268-A268. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.